Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

BACKGROUND: Secukinumab has demonstrated sustained improvement in the signs and symptoms of psoriatic arthritis (PsA) over 2 years in the FUTURE 2 study (NCT01752634). This post hoc analysis assessed the ability of secukinumab to achieve Psoriatic Arthritis Disease Activity Score (PASDAS)-based remi...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, L. C., Gladman, D. D., Nash, P., FitzGerald, O., Kavanaugh, A., Kvien, T. K., Gossec, L., Strand, V., Rasouliyan, L., Pricop, L., Ding, K., Jugl, S. M., Gaillez, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286532/
https://www.ncbi.nlm.nih.gov/pubmed/30526678
http://dx.doi.org/10.1186/s13075-018-1773-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286532/
https://www.ncbi.nlm.nih.gov/pubmed/30526678
http://dx.doi.org/10.1186/s13075-018-1773-y

Ejemplares similares